ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 209,28
-0,12%
Dow Jones
39 445,27
-0,17%
DAX
18 742,22
-0,08%
Brent Oil
83,235
1,03%
Bitcoin
63 130,04
2,74%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ALX Oncology Holdings Inc (ALXO)

  7. ALX Oncology Holdings Inc (ALXO) Actualités

ALXO

ALX Oncology (ALXO)

ALX Oncology Holdings Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALXO
DateHeureSourceTitreSymboleSociété
09/05/202422h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALXOALX Oncology Holdings Inc
09/05/202422h00GlobeNewswire Inc.ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ALXOALX Oncology Holdings Inc
08/05/202423h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
07/05/202415h00GlobeNewswire Inc.ALX Oncology Appoints Allison Dillon as Chief Business OfficerNASDAQ:ALXOALX Oncology Holdings Inc
06/05/202422h02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
30/04/202415h00GlobeNewswire Inc.ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal CancerNASDAQ:ALXOALX Oncology Holdings Inc
24/04/202416h00GlobeNewswire Inc.ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:ALXOALX Oncology Holdings Inc
09/04/202423h30GlobeNewswire Inc.ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)NASDAQ:ALXOALX Oncology Holdings Inc
07/03/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
07/03/202422h03GlobeNewswire Inc.ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ALXOALX Oncology Holdings Inc
05/03/202422h30GlobeNewswire Inc.ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual MeetingNASDAQ:ALXOALX Oncology Holdings Inc
03/01/202414h00GlobeNewswire Inc.ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALXOALX Oncology Holdings Inc
13/11/202322h05GlobeNewswire Inc.ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ALXOALX Oncology Holdings Inc
01/11/202321h05GlobeNewswire Inc.ALX Oncology Announces November Investor Conference ParticipationNASDAQ:ALXOALX Oncology Holdings Inc
10/10/202322h05GlobeNewswire Inc.ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:ALXOALX Oncology Holdings Inc
06/10/202312h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALXOALX Oncology Holdings Inc
05/10/202314h00GlobeNewswire Inc.ALX Oncology Announces Pricing of Public OfferingNASDAQ:ALXOALX Oncology Holdings Inc
04/10/202322h10GlobeNewswire Inc.ALX Oncology Announces Proposed Public OfferingNASDAQ:ALXOALX Oncology Holdings Inc
03/10/202316h03IH Market NewsKeep An Eye Out: Pre-Market Movers And RecommendationsNASDAQ:ALXOALX Oncology Holdings Inc
03/10/202312h00GlobeNewswire Inc.ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric CancerNASDAQ:ALXOALX Oncology Holdings Inc
02/10/202322h05GlobeNewswire Inc.ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric CancerNASDAQ:ALXOALX Oncology Holdings Inc
20/09/202314h45InvestorsHub NewsWirePathways to Progress: How Orphan Drug Designation Sparks Biotech TransformationNASDAQ:ALXOALX Oncology Holdings Inc
11/09/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALXOALX Oncology Holdings Inc
08/09/202322h25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ALXOALX Oncology Holdings Inc
06/09/202314h00GlobeNewswire Inc.ALX Oncology Realigns Executive Leadership TeamNASDAQ:ALXOALX Oncology Holdings Inc
01/09/202322h11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALXOALX Oncology Holdings Inc
31/08/202313h00GlobeNewswire Inc.ALX Oncology Announces September Investor Conference ParticipationNASDAQ:ALXOALX Oncology Holdings Inc
10/08/202322h01GlobeNewswire Inc.ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program UpdateNASDAQ:ALXOALX Oncology Holdings Inc
26/06/202313h00GlobeNewswire Inc.ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric CancerNASDAQ:ALXOALX Oncology Holdings Inc
22/06/202322h51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALXOALX Oncology Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ALXO

Dernières Valeurs Consultées

EU
IWHCS
ISHARES WHCS INAV
COIN
NILEUR
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés